Job Search

Latest Jobs

Purpose: Acting as the key interface with clients over projects, manages the timely delivery of project outputs in line with client expectations. Dev...

SENIOR ASSOCIATE

Purpose: Manages the delivery of client project(s), ensuring delivery of the project in line with client objectives and expectations as well as proje...

SENIOR PRINCIPAL (Strategy Group)

As a Senior Principal, you will work directly with clients to deliver projects addressing strategic issues. You will have responsibility for business development, client relationship development, thought leadership, mentoring, and ensuring delivery of high levels of client satisfaction by:

Operating as a member of the Global Leadership Team, providing leadership to globally and locally
Meeting or exceeds assigned revenue targets by developing and delivering insightful, value-added proposals that address complex client issues.
Generating leads and leading proposal development to ensure actionable, on-target and timely proposals are provided to clients.
Seeking out and identifying new revenue opportunities at existing and potential clients
Selling projects and delivering the Business Development target as both Principal in charge and bid team member
Developing and/or elevating new business opportunities through the identification of follow-on work and new leads.
Owning client engagements with responsibility for client satisfaction and delivering high levels of quality/added value
Following-up with client after project deliverable have been completed to ensure client satisfaction.
Providing direction, advice and intellectual leadership to clients and delivery teams.
Playing a significant role on account planning and strategy with sales team.
Contributing to the enhanced awareness of Consulting in the market place, e.g. through speaking engagements, client meetings, publications
Mentoring, coaching and sharing subject matter expertise with others to help develop individuals and our capabilities to deliver world-class solutions for clients
Providing direction to our teams to ensure the development of client reports and presentations
Leading thought leadership and firm building initiatives
Remaining current on industry, client and competitive trends and directions in order to anticipate and identify new business challenges and issues at assigned clients.

Senior Principal should have:

Demonstrated strong leadership skills within a global organization
Strong capability in managing projects and juggling priorities so that deadlines are met while retaining consistently high quality outcomes
Well-developed written and verbal communication skills including presentations, chairing meetings, workshop facilitation, business and report writing
Track record of ability to sell high quality, high value projects to clients
Strong capability in managing projects and juggling priorities so that deadlines are met while retaining consistently high quality outcomes
Ability to drive Business Development independently
Experience of working in sizable/ multi-disciplined teams and supervising staff
Experience of developing credible relationships with executives in the pharmaceutical/healthcare industry
Excellent interpersonal skills and ability to work effectively with others in and across the organization to accomplish team goals
Intensive experience leading, managing, and developing people
Broad understand of pharmaceutical industry
Knowledge of key issues and current developments in the pharmaceutical and healthcare industries
Thorough knowledge of consulting methodologies, tools and techniques

In addition to the skills and experience above, candidates interested in joining IMS Consulting Group as a Senior Principal should have:

A strong academic track record including minimum Bachelor’s degree or equivalent, relevant graduate degree preferred (further personal/industry qualifications are valued but are not essential)
At least 12 years professional experience in consulting, pharmaceutical and healthcare industry with evidence of career progression
Demonstrable experience in and commitment to the life sciences and/or healthcare industries
A strong track record of management, leadership and people development
A willingness and ability to travel to client locations
Fluency in English (spoken and written)
Right to live and work in the recruiting country

Job Type:

Permanent

Experience:

Bachelors Degree

Location:

London

Sector:

Commercial

Salary:

£Negotiable

Ref:

104

How to apply

Apply Now

Latest News

Penn engineers turn toxic fungus into anti-cancer compound

Fri, 27 Jun 2025 10:00:00 +0200

Penn-led researchers have turned a deadly fungus into a potent cancer-fighting compound. After isolating a new class of molecules from Aspergillus flavus, a toxic crop fungus linked to deaths in the excavations of ancient tombs, the researchers modified the chemicals and tested them against leukemia cells. The result? A promising cancer-killing compound that rivals FDA-approved drugs and opens up new frontiers in the discovery of more fungal medicines.

New drug for diabetes and obesity shows promising results

Thu, 26 Jun 2025 10:00:00 +0200

Lower blood sugar and increased fat burning - without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.

Article presents innovative drug for controlling weight and blood sugar

Wed, 25 Jun 2025 10:00:00 +0200

An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to produce heat through a process known as thermogenesis, thereby promoting weight loss. In animal tests, the compound prevented fat accumulation in response to a high-fat diet, treated existing obesity, and reversed associated metabolic disorders, including insulin resistance.

Weekly semaglutide improves blood sugar and weight in adults with Type 1 diabetes

Tue, 24 Jun 2025 10:00:00 +0200

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

The results were published in the journal NEJM Evidence.

Targeting fusion protein's role in childhood leukemia produces striking results

Mon, 23 Jun 2025 10:00:00 +0200

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML). Standard treatment is often ineffective against AML, a cancer that commonly relapses with poor prognosis, particularly when the disease is fueled by fusion proteins involving NUP98.

AI could accelerate protein engineering - key for developing new medicines

Fri, 20 Jun 2025 10:00:00 +0200

In a study published in the journal Nature Machine Intelligence, Sheffield computer scientists in collaboration with AstraZeneca and the University of Southampton have developed a new machine learning framework that has shown the potential to be more accurate at inverse protein folding than existing state-of-the-art methods.

AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research

Thu, 19 Jun 2025 10:00:00 +0200

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.

Researchers identify a protein that may help improve the treatment of obesity and cardiovascular disease

Wed, 18 Jun 2025 10:00:00 +0200

Obesity, diabetes and cardiovascular diseases are increasingly present in the population. Brown adipose tissue has a protective function against these prevalent diseases, as it burns calories and can produce body heat from fat. But as the body ages, the activity of brown adipose tissue decreases. This inactivation of brown adipose tissue - also typical of obese people - remains poorly studied in the scientific literature.

New strategy for the treatment of severe childhood cancer

Tue, 17 Jun 2025 10:00:00 +0200

Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer. By combining two antioxidant enzyme inhibitors, they have converted cancer cells in mice into healthy nerve cells. The study is published in the journal Proceedings of the National Academy of Sciences (PNAS).

Groundbreaking TACIT algorithm offers new promise in diagnosing, treating cancer

Mon, 16 Jun 2025 10:00:00 +0200

Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment of cancer and in the prescription of medicines. As recently published in Nature Communications, Jinze Liu, Ph.D., and Kevin Byrd, D.D.S., Ph.D., created Threshold-based Assignment of Cell Types from Multiplexed Imaging Data (TACIT), which assigns cell identities based on cell-marker expression profiles.

Smartphone tests could accelerate drug development for Huntington's disease

Fri, 13 Jun 2025 10:00:00 +0200

A series of digital tests, carried out via a smartphone app, could enhance the detection of disease progression in Huntington's disease and improve the efficiency of clinical trials, finds research led by scientists at University College London (UCL) and Roche.

The research, published in Brain, highlights how digitising tests designed to measure the progression of motor symptoms in people with Huntington's disease can provide a sensitive and reliable way to track changes in the function of patients.

Vividion Therapeutics and Bayer further strengthen oncology development pipeline with clinical-stage WRN inhibitor

Thu, 12 Jun 2025 10:00:00 +0200

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its innovative oncology development pipeline. VVD-214 was discovered and developed under an exclusive worldwide collaboration and license agreement initiated between Vividion and Roche in 2020.

Ultra-selective aptamers give viruses a taste of their own medicine

Wed, 11 Jun 2025 10:00:00 +0200

We have all heard of antibodies - proteins produced by our bodies to bind to viruses or bacteria, marking them for elimination by the immune system. But not all of us are familiar with aptamers: short segments of DNA or RNA that are designed to bind, like antibodies, to specific targets. Synthetic and inexpensive to produce, aptamers are attractive alternatives to antibodies for biomedical diagnostics and therapeutics.

Fermenting legume pulses boosts their antidiabetic, antioxidant properties

Tue, 10 Jun 2025 10:00:00 +0200

Food scientists at the University of Illinois Urbana-Champaign identified the optimal fermentation conditions for pulses - the dried edible seeds of legumes - that increased their antioxidant and antidiabetic properties and their soluble protein content.

Using the bacteria Lactiplantibacillus plantarum 299v as the microorganism, the team fermented pulses obtained from varying concentrations of black bean, black-eyed pea, green split pea, red lentil and pinto bean flours.

Improving T cell responses to vaccines

Mon, 09 Jun 2025 10:00:00 +0200

In the quest to design vaccines that better help the body's immune system fight disease, scientists are always looking for more tools for their arsenal. The strong antibody responses generated by vaccines provide an important first round of defense, but "you always want to have a backup plan," says Biomedical Graduate Studies Ph.D. student Emily A. Aunins, considering viruses mutate to evade antibody responses that become widespread in a population.

ISTH: new data highlight innovation from Sanofi's pipeline in rare diseases

Fri, 06 Jun 2025 10:00:00 +0200

New data from 18 abstracts, including five oral presentations, will be presented at the 33rd congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington D.C., US from June 21 to 25, 2025, highlighting Sanofi as a leader in hemophilia committed to rare blood diseases. Data to be presented expand on the potential of rilzabrutinib to address the underlying immune dysregulation of immune thrombocytopenia (ITP) and strengthen Sanofi as a leader in hemophilia with ALTUVIIIO and the newly launched Qfitlia, aimed at providing more treatment options to help improve patients' lives.

Fighting myeloma with fiber: Plant-based diet offers promise

Thu, 05 Jun 2025 10:00:00 +0200

Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study showed that the diet was not only feasible and well-received but also improved several factors that could potentially delay the progression of precancerous conditions that can lead to multiple myeloma.

Collaborations result in antibiotic resistance breakthrough

Wed, 04 Jun 2025 10:00:00 +0200

University of Otago - Ōtākou Whakaihu Waka researchers have been part of two groundbreaking studies in the battle against drug resistant strains of Mycobacterium tuberculosis, the cause of tuberculosis.

Co-author on both studies, Dr Matthew McNeil, of the Department of Microbiology and Immunology, describes tuberculosis as a "massive public health problem" that is challenging to solve.

Tea, berries, dark chocolate and apples could lead to a longer life span

Tue, 03 Jun 2025 10:00:00 +0200

New research has found that those who consume a diverse range of foods rich in flavonoids, such as tea, berries, dark chocolate, and apples, could lower their risk of developing serious health conditions and have the potential to live longer.

The study was led by a team of researchers from Queen's University Belfast, Edith Cowan University Perth (ECU), and the Medical University of Vienna.

Application of machine learning in drug side effect prediction: databases, methods and challenges

Mon, 02 Jun 2025 10:00:00 +0200

Understanding and preventing drug side effects holds a profound influence on drug development and utilization, profoundly impacting patients' physical and mental well-being. Traditional artificial drug experimentation methods are not only expensive but also time-consuming, rendering comprehensive testing a challenging task.

Upload Your CV

Need help finding that new job? Leave your details with us and request a call back from one of our consultants.

Submit A Vacancy

Looking to expand? Or a vacancy has become available in your business then let us know and we can find the right person for you